Empowering early-phase drug discovery
Silicos is a chemo-informatics-based biotechnology company empowering proprietary
multi-target virtual screening technologies for the discovery of novel and
high-quality lead compounds for the treatment of a large variety of
diseases, such as cancer, infectious diseases, central nervous system and
immunodeficiency diseases.
Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets.
More information on Spectrophores™ and Cosmos™ can be found in the Technology section.
News
Apr-2008 | Silicos publishes Pharao tool in Journal of Molecular Graphics and Modeling. Read more...
Jan-2008 | Silicos and In Silico Biosciences start collaboration. Read more...
Jan-2008 | Silicos and UCB start collaboration. Read more...
27-Nov-2007 | Silicos is looking for a computational chemist/molecular modeler. Read more...
Collaborations
January-2008 | In Silico Biosciences and Silicos start a collaboration. Read more...
January-2008 | UCB and Silicos entered into a collaboration. Read more...
Upcoming Events
02-04-Jul-2008 | Silicos will be present at Bio Expo Japan, 2008, Tokyo, Japan. Read more...
19-20-Jun-2008 | Silicos will be present at Virtual Discovery Europe, Amsterdam, the Netherlands. Read more...
17-20-Jun-2008 | Silicos will be present at Bio 2008, San Diego, USA. Read more...
6-Jun-2008 | Silicos will be present at Knowledge for Growth in Ghent, Belgium. Read more...
Contact Information
For more information about Silicos NV, contact info@silicos.com.